摘要
二氢二醇脱氢酶(DDH)为醛-酮还原酶家族成员之一,是一种胞质蛋白,在非小细胞肺癌(NSCLC)的发生发展过程中有重要作用。国内外相关研究发现,NSCLC患者血清DDH浓度明显高于非肿瘤患者,治疗前后其血清浓度有明显的变化;DDH与NSCLC的转移、预后及耐药密切相关;其可能可作为NSCLC的肿瘤标志物。同时DDH在NSCLC患者血清中异常表达的具体机制尚不清楚。因此,DDH作为血清肿瘤标志物的作用还有待进一步深入研究。
Dihydrodiol dehydrogenase（DDH）,as one member of aldo-keto reductase superfamily,was one kind of plasmo-protein.DDH played an important role in pathogenesis of non-small cell lung cancer（NSCLC）.Because the serum DDH concentration of patients with NSCLC was thicker than patients without NSCLC,and the concentration of DDH alters obviously between pri-treatment and post-treatment,and being closely related to NSCLC metastasis,prognosis and drug resistance.DDH may be the tumor markers of NSCLC.The specific mechanisms about abnormal expression of DDH in NSCLC patients also remain unclear.Thus,as the role of serum tumor markers,DDH should be a further research.
出处
《医学综述》
2011年第10期1497-1499,共3页
Medical Recapitulate
关键词
非小细胞肺癌
肿瘤标志物
二氢二醇脱氢酶
Non-small cell lung cancer
Tumor markers
Dihydrodiol dehydrogenase
